Tango Therapeutics Inc (NASDAQ:TNGX) has a beta value of 1.23 and has seen 1.77 million shares traded in the last trading session. The company, currently valued at $576.65M, closed the last trade at $5.32 per share which meant it gained $0.16 on the day or 3.10%% during that session. The TNGX stock price is -125.94% off its 52-week high price of $12.02 and 80.64% above the 52-week low of $1.03. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.88 million shares traded. The 3-month trading volume is 2.37 million shares.
The consensus among analysts is that Tango Therapeutics Inc (TNGX) is Buy stock at the moment, with a recommendation rating of 1.12. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.35.
Tango Therapeutics Inc (NASDAQ:TNGX) trade information
Sporting 3.10%% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the TNGX stock price touched $5.32 or saw a rise of 1.12%. Year-to-date, Tango Therapeutics Inc shares have moved -44.23%, while the 5-day performance has seen it change 13.43%. Over the past 30 days, the shares of Tango Therapeutics Inc (NASDAQ:TNGX) have changed 181.48%. Short interest in the company has seen 15.95 million shares shorted with days to cover at 4.87.
Wall Street analysts have a consensus price target for the stock at $13, which means that the shares’ value could jump 59.08% from current levels. The projected low price target is $13.0 while the price target rests at a high of $18.0. In that case, then, we find that the current price level is -238.35% off the targeted high while a plunge would see the stock gain -144.36% from current levels.
Tango Therapeutics Inc (TNGX) estimates and forecasts
The company’s shares have gained 82.82% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -33.09%.
7 analysts offering their estimates for the company have set an average revenue estimate of 6.42M for the current quarter. 7 have an estimated revenue figure of 6.48M for the next ending quarter. Year-ago sales stood 19.88M and 11.61M respectively for this quarter and the next, and analysts expect sales will shrink by -67.70% for the current quarter and -33.09% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 7.47% over the past 5 years. Earnings growth for 2025 is a modest -13.03% while over the next 5 years, the company’s earnings are expected to decrease by -5.61%.
TNGX Dividends
Tango Therapeutics Inc is expected to release its next earnings report on 2025-May-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Tango Therapeutics Inc (NASDAQ:TNGX)’s Major holders
Insiders own 12.59% of the company shares, while shares held by institutions stand at 97.75% with a share float percentage of 111.82%. Investors are also buoyed by the number of investors in a company, with Tango Therapeutics Inc having a total of 169.0 institutions that hold shares in the company. The top two institutional holders are TRV GP IV, LLC with over 19.2 million shares worth more than $164.75 million. As of 2024-06-30, TRV GP IV, LLC held 17.7276% of shares outstanding.
The other major institutional holder is ECOR1 CAPITAL, LLC, with the holding of over 13.33 million shares as of 2024-06-30. The firm’s total holdings are worth over $114.38 million and represent 12.3075% of shares outstanding.
